Thymoglobulin is indicated for the treatment of renal transplant acute rejection in conjunction with concomitant immunosuppression. The Sangstat press release indicates that Thymoglobulin is a polyclonal antibody. The product is manufactured by Pasteur M rieux S rums et Vaccins, S.A., and distributed by SangStat.
Acute rejection can often lead to the loss of the transplanted organ.
The recommended route of administration is intravenous infusion using a high-flow vein. Thymoglobulin should be infused over a minimum of 6 hours for the first infusion and over at least 4 hours on subsequent days of therapy. Thymoglobulin should be administered through an in-line 0.22 m filter. For vial reconstitution, dilution in infusion solution and infusion procedure, see Preparation for Administration. Investigations indicate that Thymoglobulin is well tolerated and less likely to produce side effects when administered at the recommended rate.